Current position

Cathie Wood’s Intellia Therapeutics (NTLA) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

ARK Investment ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2017Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares16.88MHighest verified quarter-end share count
Quarters reported35Verified quarters with shares above zero
What happened?

ARK Investment Management first reported Intellia Therapeutics in Q3 2017. The reported position was increased and reduced across later filings. ARK Investment Management currently reports 16.88M shares. The latest verified filing showed: Bought 16.3% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 16.3% more+2.37M shares · 16.88M shares reported after the change
Filing context

Quarter-end price $16.92 · Estimated holding basis $27.30

Q1 2026
Bought 2.1% more+301.92K shares · 14.51M shares reported after the change
Filing context

Quarter-end price $12.82 · Estimated holding basis $28.99

Q4 2025
Bought 19.2% more+2.29M shares · 14.21M shares reported after the change
Filing context

Quarter-end price $8.99 · Estimated holding basis $29.34

Q3 2025
Sold 8.4% of the position−1.10M shares · 11.92M shares remained
Filing context

Quarter-end price $17.27 · Estimated holding basis $33.24

Q2 2025
Bought 0.05% more+6.86K shares · 13.02M shares reported after the change
Filing context

Quarter-end price $9.38 · Estimated holding basis $33.24

Q1 2025
Bought 3.8% more+474.63K shares · 13.01M shares reported after the change
Filing context

Quarter-end price $7.11 · Estimated holding basis $33.26

Portfolio importance

How important is Intellia Therapeutics in ARK Investment Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight1.9%Q2 2026
Current rank#17of 190 reported positions
Peak portfolio weight5.0%Q3 2018
Best historical rank#2Q3 2018
At peak importanceQ3 2018
NTLA
5.0%
Largest holding
6.0%
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$12.142026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$16.92Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$27.30Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Intellia Therapeutics stock page →

This tracker follows ARK Investment Management’s aggregated Form 13F disclosures. It is not Cathie Wood’s personal brokerage account, and 13F filings do not reveal exact trade dates or execution prices.